The PRWIRE Press Releases https:// 2020-07-09T00:57:00Z JIC White Paper - Enabling the digital transformation of healthcare 2020-07-09T00:57:00Z jic-white-paper-enabling-the-digital-transformation-of-healthcare Brussels, 7 JULY 2020. The Joint Initiative Council for Global Health Informatics Standardisation (JIC) has published a white paper explaining how its nine health informatics standards development organisations (SDOs) have been working together to help transform the global healthcare system into one that’s digital with the goal of precise and real-time exchange of information based on full interoperability enabled by global standards. Transcending national boundaries and organisations, the Joint Initiative Council’s SDOs work collaboratively to provide global, coordinated—not competitive—standards that address real-world healthcare issues. In its recently released white paper, the JIC explores the desired future of a digital health ecosystem where high-quality data is available to the right people, at the right place and at the right time for high-quality decisions and care. Established in 2007 and consisting of nine SDOs, including CDISC, CEN, DICOM, GS1, HL7, IHE, ISO, LOINC and SNOMED International, the Joint Initiative Council has come together to deliver coordinated standards and implementation guides. Today, healthcare researchers, manufacturers and providers can use these JIC outcomes for the successful implementation of digital processes and interoperable systems. “At JIC, we recognise the importance of consistency across standards and the need to collaborate on their development. We’re concerned not only about standards as ‘outputs,’ but more importantly, how standards impact healthcare ‘outcomes’—their practical value in the delivery of high-quality care,” said Ulrike Kreysa, senior vice-president, GS1 Healthcare and chair of the JIC. Within the context of the global COVID-19 pandemic, the need for accelerating the speed and capacity of this digital transformation has become more important than ever before. JIC members are contributing to this public health need by addressing immediate gaps and by providing topical enhancements to their existing standards. "The World Health Organization (WHO) looks forward to the continued cooperation of global Standard Development Organisations within the Joint Initiative Council in order to better leverage on common health data standards and interoperability to anticipate and react to pandemic challenges such as the one we are experiencing, and to the future ones to come in our fast and ever-changing environment.”, said Bernardo Mariano Junior, Director, Digital Health & Innovation and Chief Information Officer, World Health Organization. Joint Initiative Council for Global Health Informatics StandardisationHighlights from the JIC white paper include four standards-based initiatives that offer practical solutions to real-world problems. These initiatives include the International Patient Summary (IPS), the Identification of Medicinal Products (IDMP), COVID-19 and Genomics. The white paper is available as a downloadable PDF at For more information, visit the JIC Web page: or follow us on Twitter @JICouncil. JIC Media Contact Philippe NeirinckxDirector Marketing Healthcare, Emerging Sectors & Solutions T: +32 2 788 78 00 E: About the Joint Initiative Council - The Joint Initiative Council for Global Health Informatics Standardisation (JIC) is formed to further the important role of health informatics standards to enable interoperability of information and processes across health domains. Health informatics standardisation is supported by a community of experts that works within and across various health informatics standards development organisations (SDOs). The JIC supports the timely, efficient delivery of safe, coordinated, accountable, high-quality health services to individuals, communities and populations. www.jointinitiativecouncil.orgAustralian media enquiries:Wendy McWilliams, WMC Public Relations Pty Ltd. Tel: 03 9803 2588. E: copy of the white paper can be downloaded from WMC PR’s Press Office: Max Kelsen Achieves AWS Machine Learning Competency Status 2020-07-07T03:56:37Z max-kelsen-achieves-aws-machine-learning-competency-status Brisbane, 7 July, 2020 – Max Kelsen, Beyond A.I., one of Australia’s leading Machine Learning (ML) solutions businesses, and an APN Advanced Consulting Partner, announced today it has achieved Amazon Web Services (AWS) ML Competency status as part of the AWS Partner Network (APN). This designation recognises Max Kelsen’s ability to deliver ML solutions in production on AWS, enabling customers to generate business value and increase competitive advantage. Brisbane-based Max Kelsen is only the third APN Partner in Australia to achieve the AWS ML Competency status and it is a significant reflection of the company’s investment in resources and skills made to maximise the full suite of AWS ML services. The competency has enhanced Max Kelsen’s ability to deploy industry relevant, in-production solutions for customers globally, across a wide range of industries including healthcare, financial services, retail, travel, and the public sector. Nick Therkelsen-Terry, CEO, Max Kelsen, said the AWS competency builds on the company’s history of providing solutions which help customers solve their data challenges, deploy ML and data science workflows, and offer Software as a Service (SaaS) and Application Programming Interface (API) based features to enable predictive capabilities within their applications. “Achieving AWS ML Competency status demonstrates to our customers that Max Kelsen has validated expertise in ML experience on AWS,” Mr Nick Therkelsen-Terry said. “We have a proven track record of delivering game changing ML products and services for our customers.” He said. Davinia Simon, Head of Channel and Alliances in Australia and New Zealand, AWS, said, “Whether it’s improving customer experience, helping people discover entertainment easier, or predicting when maintenance is needed in industrial equipment, ML capabilities are extremely important for organisations to solve some of the toughest challenges. ML is an incredibly exciting area of emerging technology, and we are thrilled to see our APN Partners like Max Kelsen specialising in this technology to support their customers.” Max Kelsen has developed ML as a Service (MLaaS) as a joint investment approach with its customers, where both parties collaborate to build innovative solutions. Once developed, these MLaaS solutions are delivered via a consumption-based pricing model, with defined outcomes. This model can help to support organisations with capital expenditure constraints that are limited by COVID-19, while the imperative for businesses to innovate has never been greater. About Max Kelsen Founded in Brisbane in 2015, Max Kelsen (MK) is one of Australia’s leading Artificial Intelligence (AI) and Machine Learning (ML) solutions businesses. We deliver innovation which is directly linked to the generation of business value and competitive advantage to customers in Australia and globally, including Fortune 500 companies. Max Kelsen is also dedicated to reinvesting our expertise and profits to solve the challenges of humankind, focusing on Cancer Genomics, AI Safety, and Quantum Computing. Media Contact: Peter Witts. Email: Ph +61 (0) 477274412 Young couple raise over $20K for Synovial Sarcoma research ahead of NATIONAL SARCOMA AWARENESS MONTH 2020-06-26T00:24:09Z young-couple-raise-over-19k-for-synovial-sarcoma-research-in-just-weeks-ahead-of-national-sarcoma-awareness-month · *  July is Sarcoma Awareness Month *  Young couple raise over $20K for Synovial Sarcoma research in just weeks    *  Epidemiology PhD Candidate Max Qua shaves off her incredible long hair as her partner Matt recommences chemo. Max Qua is a high achieving young Western Australian woman with a very good reason to brave the shave – to raise much needed funds for research into Sarcoma – an extremely rare cancer that represents just 1% of all known cancers. Her partner, Matthew Eton, is battling synovial sarcoma - a subtype of this rare cancer – for the second time in just five years. With Matt is due to lose his hair again, Max Qua, 24, thought she would do the same. The pair created a Facebook fundraising page last week  - Max and Matt go Bald for Sarcoma Research – and have to date raised over $18K for local charity Sock it to Sarcoma.   Her dead straight, waist long uncoloured jet-black hair has not been cut for over five years, and with her ponytail likely to measure in at well over 40cm, it is highly valued by wig makers.    Matt, 23, was first diagnosed with Synovial Sarcoma at just 18 years of age. Now after five years of clear scans, the cancer is back. “Back in the first half of 2015, I underwent surgery, followed by four months of chemotherapy and three months of radiotherapy - all during my second year of uni, “ said Matt, who continued to study towards his electrical engineering and business law degree at the University of Western Australia (UWA) during treatment. However, raising money and awareness for cancer charities is nothing new for Matthew.   In 2015 he entered Run for Reason and managed to complete 5km while undergoing chemo. He was a volunteer organiser for the Cancer Council Relay for Life on campus at UWA.  As he completed his degree, he turned his attention to a topic for his honours thesis that could make a difference and focused on medical imaging – specifically analysing breast cancer imaging techniques for use during surgery. He even worked as a research assistant with the breast cancer imaging group for the second half of 2018. He finished his studies, earning a Bachelor of Philosophy with First Class Honours. He was also one of the University of Western Australia top prize winners in 2018 – being awarded the prestigious Dr Vincent Harry Cooper Memorial Prize for his honours dissertation on Sub-surface Feature Characterisation Using Simulated Optical Palpation and completed his honours in biomedical engineering. Matthew spent six months working as a researcher with BRITElab at the Harry Perkins Institute of Medical Research and currently works with Azure Consulting in Perth, who are being very understanding and supportive as he battles Synovial Sarcoma for a second time. A medical researcher herself, Max knows all too well just how needed targeted research funding is. Her Master of Biomedical Science included a thesis focusing on HIV and immunogenetics, and she is currently studying towards her Doctorate in Epidemiology. “We aimed high and thought we could raise around $5,000,” said Max, noting that both she and Matt will be shaving their heads. That initial target was soon exceeded in a few hours, and within just one day they had raised over $13K.  As of this morning, they have raised over $20K. “I’d like to think we could raise $30k – it’s a year’s salary for a PhD scholarship,” said Max. “When Matt was diagnosed just over a month ago, I did a big trawl through all the scientific literature I could find about this particular type of cancer.   “I realised that relative to many other cancers and medical conditions, the science of sarcoma is not too well understood, with comparatively limited research. There are gaps that need to be filled, and a scarcity of funding available to fill them. “We are both pretty fit, so when Matt was suddenly experiencing abdominal pain and turned very pale, we suspected that something was not right,” said Max, who happens to be one of Australia’s top Ultimate athletes – in fact she is a former Australian Beach Ultimate Team Captain and currently represents Australia as the ambassador for the Academy International University Sports Federation (FISU). Matt was admitted to hospital with internal bleeding from a tumour 17 May 2020 and has spent four weeks in hospital. He started chemotherapy again last week and is undergoing his second dose today. This dedicated young pair have a real battle on their hands, but they are strong and are bravely facing this next challenge together – they are ready to Sock it to Sarcoma! Matt is fortunate to have such a strong support network with Max, his friends and family, and behind them the team at Sock it to Sarcoma who have helped his family over the past five years. His mum, Jane, even arranged a loan of a pair of hair clippers from a hairdressing friend – suspecting that Matt’s beard trimmer may not be able to handle the sheer amount of hair that Max is about to remove! “I've never really believed in getting haircuts,” said Max, whose hair is currently extremely long and usually tied in a high twist. “We’ve added a quiz to our Facebook fundraiser to see if anyone can guess how much five years’ worth of hair might weigh,” said Max, noting that as they are both top level Ultimate Frisbee players, the prize is a disc signed by both Max and Matt.   “I am still working out what to do with the hair. I can donate it, but I am aware that really long donated ponytails are often on-sold, so we are hoping an honest local wig maker can offer us a fair price and that money can further bolster our fundraising efforts,” said Max. It’s all coming off tomorrow – on Saturday 27 June – just ahead of Sarcoma Awareness Week & Sarcoma Awareness Month – both of which commence next week.  Due to social distancing, and as Matt will be immuno-compromised due to his treatment, the pair plan to livestream Matt shaving Max’s head at 1pm Perth time.  Donations will continue through until 8 July 2020. To donate, visit: Max and Matt go bald for Sarcoma research at: Vaccine testing - faster and better 2020-06-18T12:51:30Z vaccine-testing-faster-and-better The Editor, Dear Editor, Like many Australians of a certain age I’m spending most of my time at home, hoping a COVID-19 vaccine will be available very soon. The CSIRO, usually at the cutting edge of science and technology research in this country, is wasting precious time squirting the virus up ferrets’ noses! Ferrets don’t go to protests or footie matches, so let’s leave them alone! Testing on non-human animals is not only unethical, it is scientifically unjustifiable. The US National Institutes of Health (NIH) reports that 95 out of every 100 drugs that test safe and effective in animals never make it through human clinical trials. Tests on animals are no guarantee of human safety, and this was tragically illustrated in the 2006 clinical trial for the immunomodulatory drug Theralizumab, where six human volunteers suffered multiple organ failure after receiving a dose 500 times smaller than that found safe in animal tests. Thankfully, medicines regulators – including the Therapeutic Goods Administration – are waking up to this and have decided that some COVID-19 vaccines can go directly to human trials without waiting for the results of certain lengthy and deadly animal tests. Innovative, non-animal research methods, combined with responsibly conducted tests on human volunteers, are the surest route to effective treatments and vaccines. Unlike humans, animals can’t agree to being experimented on. They are born and die in a laboratory and spend the intervening time in small, bleak cages, denied all freedom and autonomy. In these secret, high security institutions, they may be infected with the virus, then force-fed or injected with drugs for days or weeks before being gassed to death and dissected. Not in our name, not on our time. Stop this cruel, archaic wastage, and go straight to human tests. Desmond Bellamy Special Projects Coordinator PETA Australia PO Box 2352 Byron Bay NSW 2481 0411 577 416 Australian based temperature sensor manufacturer assists in times of crisis 2020-05-19T05:00:48Z australian-based-temperature-sensor-manufacturer-assists-in-times-of-crisis Australian owned temperature sensor manufacturer, Pyrosales, is operating at critical capacity during the current COVID-19 pandemic. As Australia’s longest established manufacturers of precision temperature, level and flow measurement gauges, sensors and instrumentation, as well as calibration devices, they are helping out the essential services in need. When it comes to the Australian essential services, Pyrosales has always worked with them, even before the pandemic. Assisting with supply and manufacture for the Medical Industry, the most common products are the infrared thermometer to measure the temperature of individuals in a quick and accurate manner and thermal imaging devices that can detect variations in temperature of individuals. Hospitals and private medical businesses can rely on the team at Pyrosales to supplying refrigeration temperature equipment for medicines, blood and IVF storage as well as maintaining the equipment for sterilization, and of course food temperature control. They are also working to help our aged care facilities to control the temperature of their food and medicine. Pyrosales continue to help out the essential services by ensuring food plant manufacturers have adequate thermocouples, RKC temperature controllers, temperature and pressure gauges to maintain food production. “We have solutions for businesses to monitor their employees for fever temperature. Companies are investigating new ways to measure for the virus to reduce the spread into their workplace. Pyrosales has many products to suit any businesses requirements whether it is to meet the volume of employees, their price range or on-site technology. We not only supply to the medical and industrial market, we are also seeing an increase in demand for people to use in their homes,” said our CEO, John Shanahan. With many businesses in Australia struggling in the current climate, it is positive to see an Australian owned business working not only to help those who need it but are helping boost the economy and keep people in jobs. About Pyrosales Pyrosales is Australia’s longest established and largest manufacturers of precision temperature, level and flow measurement gauges, sensors and instrumentation, as well as calibration devices. The company has developed a reputable position in Australia and internationally as a leading provider of specialist design, manufacture and repair services, especially in applications involving extreme heat conditions. Proudly Australian-owned, Pyrosales has operations in Sydney, Melbourne and Brisbane as well as in South America, China and the United States. The company remains a leading exporter of temperature sensors to Singapore, Philippines, Indonesia, Thailand, Hong Kong, India, China, Belgium, Germany, Malaysia, Zambia, South Africa, Sri Lanka and South America. Pyrosales now has 28 employees, with many having been with the company for 20 years or more. Their knowledge and understanding of the customers’ requirements ensure that a solution for their temperature needs can be provided no matter the difficulty. This service to Australian Industry has both been recognised and rewarded as recipients of business awards and finalist selections: Winner - 2009 Suncorp Business of the YearWinner - 2009 Suncorp Award for Excellence in Developing an Export MarketFinalist - 2009 Australian Institute of Export - Premier's NSW Export Awards Finalist - 2018 Australian Institute of Export - Premier's NSW Export Awards Interview Opportunities: COVID-19 and The Westmead Institute for Medical Research (WIMR) 2020-05-03T22:00:00Z interview-opportunities-covid-19-and-the-westmead-institute-for-medical-research-wimr-1 Interviews available on the topics of: We hear a lot about COVID-19 vaccine development. Why is it important to tailor vaccines for different members of the community?Spokespeople: Professor Tony Cunningham AO and Professor Sarah PalmerIn the race to develop a COVID-19 vaccine, how are WIMR’s researchers supporting the Westmead Health Precinct and global partners?Spokesperson: Professor Philip O’Connell Introducing The Westmead Institute for Medical Research Spokespeople: Professor Tony Cunningham AODirector, Centre for Virus Research and the immediate past Executive Director of WIMR“In the past, we have been able to contribute to highly effective vaccines for the most vulnerable people. Our skill set means it is our responsibility to help.”Professor Cunningham is an infectious diseases physician, clinical virologist and scientist, internationally renowned for his research on the immunobiology of HIV and herpesviruses, his work on vaccine and microbicide development, and as an antivirals expert.Professor Cunningham has had extensive experience in vaccine development – he is now using these skills as he works toward developing a vaccine for COVID-19, targeted at older at-risk individuals. Professor Sarah PalmerDeputy Director of the Centre for Virus Research“As a medical virologist, I am driven to apply my skills to develop therapies and save lives in the face of this crisis.”Professor Sarah Palmer is a medical virologist and Co-Director of the Westmead Institute Medical Research’s Centre for Virus Research. Her research has focused on understanding the genetic characteristics and dynamics of persistent HIV across a range of tissues and cells. The goal is to develop interventions designed to reduce persistent HIV reservoirs and inform HIV eradication strategies.Individuals with weaker immune systems, such as the elderly, and those with underlying health conditions like HIV, are most vulnerable to COVID-19. Professor Palmer is turning her expertise toward developing a COVID-19 vaccine that could benefit these individuals. Professor Palmer and her team hope to identify key parts of viral proteins that stimulate a protective response against all genetic variants of the virus worldwide. Professor Philip O’ConnellExecutive Director – The Westmead Institute for Medical Research“Globally, researchers are working around the clock to find a cure and develop treatments for COVID-19. Australia, and in particular The Westmead Institute for Medical Research, is playing an important role in these urgent endeavours. There are many challenges ahead, including the need for immediate and ongoing research funding. “While a vaccine or cure for COVID-19 is some way off, each new finding adds another piece to the puzzle. This disease is not going be cured by a single institution or single researcher. It will require the collective efforts of many groups, around the world, towards a single objective. This is something that WIMR does well.”Professor O’Connell is the Executive Director of WIMR, and his research is focused on the development of islet transplantation as a mainstream treatment for type 1 diabetes, as well as the use of genomics as a marker of renal transplant rejection and other complications. The Opportunity:Access to leading Australian medical experts available to provide commentary on COVID-19. About The Westmead Institute for Medical ResearchThe Westmead Institute for Medical Research (WIMR) is a leading Australian Medical Research Institute. WIMR’s mission is to liberate people globally from the burden of serious illness and disease. WIMR delivers on its mission by investigating the most pressing health issues of our time, and translating research findings into better preventions, diagnostics, treatments and cures. Closely affiliated with Westmead Hospital and The University of Sydney, WIMR research is focused on delivering the best possible outcomes for patients. Forming part of the thriving Westmead Health Precinct, WIMR’s impact stretches far more broadly, improving health outcomes for people throughout the world. WIMR is keen to identify both individuals and organisations with financial capacity and a keen interest and the motivation to support medical research.*** Distributed on behalf of The Westmead Institute for Medical Research by QUAY Communications. If you would like to speak with any of the medical experts listed, please contact: Cheryl Pettinau Emma NorgroveQUAY Communications QUAY 157 714 0499 688 001 ACROMAG – NEW SFF Embedded Computer Mates COM Express Type 10 CPU with Four Industrial I/O Modules for Signal Processing and Control Tasks 2020-04-23T04:22:21Z acromag-new-sff-embedded-computer-mates-com-express-type-10-cpu-with-four-industrial-i-o-modules-for-signal-processing-and-control-tasks-1 Acromag introduces a new rugged, small form factor (SFF) embedded computer system with modular I/O for signal processing, communication, and control functions. The ARCX1100 is optimised for size, weight, power, and cost (SWaP-C) with a COM Express Type 10 CPU and four slots for Acromag’s plug-in AcroPack® I/O modules. Overall size with an integrated removable SSD bay is just 19.3 x 19.3 x 8.2 cm and 2kg. Fanless, extended temperature operation from -40 to 71°C is supported with an Intel® Atom® E3950 (Apollo Lake) processor and four AcroPack I/O modules installed. Peripherals include two RJ45 gigabit Ethernet, two USB 3.0, two RS232, mini DisplayPort, and audio ports, plus M.2 and SATA data storage connectors. Four 68-pin VHDCI connectors securely route field I/O to the AcroPack modules without any loose internal cables to interface a mix of analogy, digital, serial, FPGA, avionics, and other I/O signals. Designed for defence, industrial, and mobile embedded computing systems, the ARCX1100 is ideal for test & measurement, data acquisition & control, communication, avionics, simulation, and signal processing applications. The rugged design is engineered to withstand 50g shock and 5g vibration. More than 25 AcroPack modules are available to perform A/D, D/A, discrete I/O, RS232/485, MIL-STD-1553, CAN bus, Gigabit Ethernet, and other functions. Third-party mPCIe modules are supported for use in the AcroPack slots. Power is sourced from a 10-36V DC supply. A water-resistant connector cover is also available to seal and secure the cabling. Compact, rugged, and extremely versatile, the ARCX1100 provides high-performance embedded computing in a simple, affordable package. The modular design combining a low-power mini COM Express processor with up to four AcroPack I/O modules offers unprecedented flexibility and upgrade-ability without compromising reliability. AcroPack mezzanine modules improve on the mini PCI Express by adding a down-facing 100-pin connector that securely routes the I/O through a carrier card to its integrated external connectors; therefore, eliminating internal cables and metalwork modifications. Carrier cards for rackmount, field-deployable, industrial chassis, desktop, and small mezzanine computing platforms let you combine up to four I/O function modules on one computer board. More than 25 models are available for data acquisition, signal processing, test & measurement, command/control, and network communication applications. Furthermore, software tools support embedded applications running on Linux®, Windows®, or VxWorks® operating systems.   ACROMAG is represented in Australia and New Zealand by Metromatics Australian Company Bigmate Launches “Thermy™” - Thermal Screening to Detect People with Elevated Temperatures 2020-04-02T04:54:37Z australian-company-bigmate-launches-thermytm-thermal-screening-to-detect-people-with-elevated-temperatures Brisbane, Australia –April 2, 2020 Brisbane based computer vision leader Bigmate, today announced the commercial availability of a pre-screening solution using thermal imaging, which immediately detects elevated temperatures of people entering or leaving workplaces in real time. Unique in its ability to scale, “Thermy” can be quickly and easily deployed in a wide range of facilities, including factories, territorial borders, warehouses, government and private offices, and any location where people are moving through entrances and walkways. Thermy uses thermal cameras and advanced analytics to provide a pre-screening observational solution which helps identify people who present the risk of an abnormal temperature. Persons in question could have their core body temperature validated, utilising the organisation’s normal medical and/or Operational Health and Safety procedures. Mark Shield, Bigmate’s Managing Director, said; “With Thermy, organisations can create a pre-screening detection system to identify people with skin-elevated temperatures, which in turn minimises the risk of impact to workplace environments. Keeping workers safe is what Bigmate is all about and this technology can assist businesses keep their workplace healthy and productive. We are excited that this industry leading product has been developed in Brisbane and proud we are able to do our small part at this challenging time.” Thermy is able to identify a ‘true skin view’ even when the subject may have a beard, a hard hat, or a protective suit which covers the body - or other features which often reduce the ability to take an accurate reading from traditional thermal camera-based solutions. Thermy also eliminates the problem of ‘flaring’ which occurs when an image is recorded in places of extreme temperature variation, by removing the background object from any analysis, focusing on the person. Thermy can also operate at scale, by detecting one or many people with elevated temperatures simultaneously. This is one of Thermy’s market-leading innovations. Thermy also utilises “edge” network services so it can still function if a network connection fails. Thermy is based on Bigmate’s “Warny” solution, which uses sophisticated computer vision algorithms developed over a number of years, to protect people working around dangerous machines, such as forklifts, trucks or industrial cutting machines. Warny is used by some of Australia’s leading industrial companies to detect instances of spontaneous combustion of materials, overheating of equipment and fires in the workplace. Warny features a number of globally-leading innovations. For example, it is unique in its ability to create distance measurement from one camera, through Bigmate’s industry leading software. This allows for the extremely accurate measurement of individual skin temperature, social distancing, and people counting. One of the ways in which Thermy logically extends Warny’s capabilities is by using thermal cameras, providing real time information through dashboards, hosted in Australia on Amazon Web Services (AWS) for remote viewing and trend analysis. If someone with an elevated temperature profile is identified, an alert will be sent via multiple media, aligned to the company’s workplace health and privacy policies. “Thermy is not intended to be a medical apparatus. It is observational technology but it is designed to play a critical role in helping organisations speed up their ability to protect workers and their families in the fight against highly contagious virus outbreaks such as COVID19, the everyday day flu and beyond,” said Mr Shield. About Bigmate: Established in Queensland, Australia in 1996, Brisbane based Bigmate is a business outcome focused technology and services company. Over that time Bigmate has established a proven record in the provision of critical risk management solutions using computer vision and industrial sensors. Our focus is keeping workers safe using technology, which in turn helps to drive productivity in some of Australia’s largest companies, government and local government. Bigmate is an Amazon Web Services Partner, providing Bigmate with access to AWS’ industry leading services, its scale, flexibility and speed to market. For further information or an interview please contact Peter Witts Sydney Director, Technology Navigate Communication Ph + 61 477 274 412 BOC and EWM celebrate decade with Industry 4.0 events 2020-03-03T01:07:51Z boc-and-ewm-celebrate-decade-with-industry-4-0-events Leading gas and engineering company BOC, a subsidiary of Linde plc, celebrated 10 years of partnership with EWM through a series of February events showcasing the latest welding innovations to Australian fabricators and businesses. In partnership with Weld Australia, BOC customers and members of Weld Australia attended ‘Discover the Welding 4.0 revolution’ which featured live welding demonstrations by digital welding experts from EWM, a global market leader in welding technology. Tony Newnham, Head of SPW Group & BOC Welding Business said the event demonstrated how Welding 4.0 techniques can improve profitability and quality for Australian welders. “Welding technology is undergoing revolutionary change with the emergence of more automation and data exchange between machines. “Whether it’s small fabrication jobs or automated robotic applications, BOC understands the need to keep our customers up to speed on the latest developments in digital welding. These technologies are revolutionising how welders deliver quality jobs. Welding operations of all sizes can increase production efficiencies and save money. “We are delighted to have our long-standing partner EWM deliver training in Australia and demonstrate their new range of Titan welding equipment, designed to future-proof welding operations for industry 4.0.” Supervisory Board, President of EWM, Susanne Szczesny-Oßing says that shared values and BOC’s expertise has been key to the successful partnership. “BOC’s technical expertise in welding and EWM’s passion for technology are the perfect combination to help our customers on their journey through this digital revolution. “Welding 4.0 has many benefits such as increased quality welds and improved production efficiency. The customers who attended the event in Sydney got exclusive demonstrations on how welding 4.0 can help them improve efficiencies in their own welding businesses. “To date, our trusted partnership with BOC has led to almost 15,000 EWM welding machines currently being used by customers in Australia and New Zealand, and we look forward to building on this partnership in the future. “The implementation of i4.0 advanced welding technology into Australian manufacturing will deliver significant improvements in profitability, efficiency and quality, “said Geoff Crittenden, CEO of Weld Australia. “Importantly, it will also make our manufacturing more internationally competitive and lead to industry growth and higher employment,” Crittenden said. New product from EWM As the exclusive distributor of leading German welding brand EWM, BOC now offers EWM’s new range of Titan welding equipment that features Rapid Response Control (RRC), intelligent monitoring and real-time welding data to ensure the highest levels of quality and efficiency. EWM demonstrated their new range of Titan welding equipment to BOC customers and Weld Australia members and will showcase it at a similar event in Brisbane on February 26th. EWM’s Titan welding equipment is now available in Australia. For more information ring 131 262 or visit -ENDS- About BOC: BOC is a subsidiary of Linde plc which supplies compressed and bulk gases, chemicals and equipment around the globe. The company develops safe, sustainable and innovative solutions for customers in many specialty sectors, heavy industry and medical environments. For more than a century the company's gases and expertise have contributed to advances in industry and everyday life, including steelmaking, refining, chemical processing, environmental protection, wastewater treatment, welding and cutting, food processing and distribution, glass production, electronics and health care. For further information, see About Linde: Linde is a leading global industrial gases and engineering company with 2019 sales of $28 billion (€25 billion). We live our mission of making our world more productive every day by providing high-quality solutions, technologies and services which are making our customers more successful and helping to sustain and protect our planet. The company serves a variety of end markets including aerospace, chemicals, food and beverage, electronics, energy, healthcare, manufacturing and primary metals. Linde's industrial gases are used in countless applications, from life-saving oxygen for hospitals to high-purity & specialty gases for electronics manufacturing, hydrogen for clean fuels and much more. Linde also delivers state-of-the-art gas processing solutions to support customer expansion, efficiency improvements and emissions reductions. For more information about the company and its products and services, please visit Further enquiries: Cora Lanigan 0410 206 634 Microba co-founder and gut analysis expert to head microbiome research at QUT 2020-02-28T04:47:38Z microba-co-founder-and-gut-analysis-expert-to-head-microbiome-research-at-qut Professor Tyson is a leading expert in environmental and human microbiome analysis, with a career in microbiology spanning across more than 20 years within Australia and the United States. In 2017, Professor Tyson with co-founder Professor Philip Hugenholtz, established Brisbane biotech Microba. Professor Tyson was also most recently the Deputy Director of the Australian Centre for Ecogenomics (ACE) at The University of Queensland and has had more than a hundred papers published in reputable journals in the space. Professor Tyson will lead microbiome research projects and take up an appointment as a Professor within the School of Biomedical Sciences at QUT as they look to expand their microbiome research capabilities. Professor Tyson said he looked forward to bringing microbiome research excellence to QUT and also setting up the framework for world-leading microbiome course content for future budding microbiologists and bioinformaticians. “The public awareness of the importance of microbiome is increasing, and our aim is to understand the role that different microorganisms play in health and disease states,” he said. “Making microbiome research accessible to more Australian researchers and also bringing knowledge to future students is key to seeing our understanding grow to the point where we will see diagnostics and therapeutics developed that will have a global impact. “Ensuring that momentum continues in this important health space is integral to a future where those with diseases with links to bacteria living on or in them have access to quick and effective diagnostics, and life-changing therapeutics.” Microba CEO Blake Wills said he was pleased to see Professor Tyson take up the new role at QUT and lead a team of microbiome-focused researchers. “We are very proud of Gene and his contributions to microbiome research, including our ongoing work at Microba in developing diagnostics and therapeutics for conditions such as IBD,” he said. “I look forward to seeing Gene’s expertise continue to inspire both students and researchers within microbiome research and Australia’s tertiary curriculum.” QUT Vice-Chancellor and President Professor Margaret Sheil said she was pleased Professor Tyson had joined the team at the university. “Professor Tyson has been a leader in microbiome research and it will be exciting for our students to work with him and his team,” Professor Sheil said. Microba has assisted more than 10,000 Australians to explore their gut bacteria since 2018 and received the Brisbane Lord Mayor’s Award for Product Innovation in 2019.   ENDS Supercharged medical community to unite against urgent threats to global health 2020-02-20T02:03:39Z supercharged-medical-community-to-unite-against-urgent-threats-to-global-health-2 Inspired to make meaningful change on global health issues, Intensive Care Specialists, Oliver Flower and Roger Harris from Sydney’s Royal North Shore Hospital have founded Coda – a global community of medical professionals dedicated to generating, proving and sharing revolutionary health care ideas for societal change. Backed by global health organisations, hundreds of volunteers and built on the highly successful conference series SMACC (Social Media and Critical Care), which travelled the globe from 2013-2019 accumulating 50,000 members, Coda begins where SMACC left off. The first-ever Coda conference will be held in Melbourne from 28 September to 2 October, uniting the entire healthcare community unbound by critical care. Each year, Coda will identify a specific and urgent threat to global health and deliver a draft set of tangible, achievable and sustainable actions for the community to build upon prior to the major event, with final action plans presented at the Coda conference for rapid adoption. Published via academic journals and disseminated across the community, these actions will be open for industry-wide comment, engagement and discussion via social platforms. In 2020, Coda will focus on an action agenda for climate change. Asking for a call-to-arms, Roger Harris said, “There are 60 million health care workers around the world, and as an industry, we’re leaders in society – the people who the public trust with their health, wellbeing and their lives. “Imagine if this community could come together as one to make positive and actionable change on global health crisis. We as a medical community can change humanity’s global footprint. We have the power to inspire, revitalise and provide hope for the future.” Connecting this to how Coda 2020 will have an impact, Oliver Flower said, “Coda was created to accelerate progress toward better health outcomes for all. We exist to create a healthier world together, however, to make real changes – we need fast action, not just talk. We will use Coda 2020 as a launchpad to mobilise our local and global communities – it will be the benchmark for real change.” Over an intensive five days, beginning with 40 CPD workshops, more than 50 expert speakers from across the globe will connect across four central domains at Coda 2020: Coda Earth: Threats to humanity from climate change, water and food shortages, and air pollution. Coda Cure: Threats include sepsis, pandemics, trauma, communicable disease. Coda Educate: Threats include equitable access to learning, knowledge dissemination, harms of medical misinformation particularly on vaccine hesitancy and antibiotic resistance. Coda Ethics: Threats include equity within healthcare itself, artificial intelligence, end of life care, population and genetic modification. Coda 2020 will provide a hub for the medical profession to come together to accelerate change, be empowered and make a real impact on local and global health issues. You can be the first to secure your seat at Coda 2020 from 1st April (no joke) – get in quick at #Coda2020 @codachange -ENDS- Notes to editors: Interviews are available upon request with Coda Co-Founders Roger Harris and Oliver Flower About Coda: Coda is a global community that comes together to generate, prove and share revolutionary ideas to solve urgent global health challenges. Founded by the same team that created the SMACC (Social Media and Critical Care) worldwide conference series - which ran from 2013 – 2019 visiting Australia, Chicago, Ireland, Germany - the Coda community is driven by four key values: collaboration, action, creativity and humanity. Coda 2020 is a supercharged medical conference for professionals in the health community. It is built on a desire to improve health outcomes across the world, and the opportunity to convert that desire into action. Coda 2020 will deliver: A captivating and thought-provoking healthcare program. Incredibly inspiring speakers with compelling messages. A huge variety of program formats to stimulate and engage. Unparalleled production qualities guaranteed to capture your attention. Unforgettable social events to relax, recharge and connect. A community experience that is diverse and inclusive in every way. Roger Harris Roger Harris is a senior staff specialist in the intensive care unit at the Royal North Shore Hospital and the Sydney Adventist Hospital (SAN). He is dual qualified in Emergency Medicine and Intensive Care. Roger is one of the co-founders of Coda and SMACC (Social Media and Critical care). He is passionate about education, his five children and especially his beautiful wife Georgie. Oliver Flower Oliver Flower is a staff specialist in Intensive Care Medicine at Royal North Shore Hospital, Sydney. He is an intensivist in Sydney who’s been driving SMACC (Social Media and Critical Care), and now Coda, from their beginnings. He has steered the creative side of SMACC & Coda, from the graphic design elements to the style, marketing, website and social platform strategies. He has an interest in neurocritical care and has shaped the neuro workshops. Media Contacts: For further information, images, interviews or industry commentary, please contact ZADRO: Debbie Bradley, Group Account Director | 0420 761189 | Event Contacts: For event and registration, please contact Coda: Phone +61 2 9431 8600 Email Website MRI PRO ANNOUNCES GLOBAL RESELLER AGREEMENT WITH SIEMENS HEALTHINEERS 2020-02-18T21:40:47Z mri-pro-announces-global-reseller-agrement-with-siemens-healthineers PEPconnect (Personalized Education Plan), an online platform providing thousands of learning modules on imaging and laboratory diagnostics, now offers access to additional education content to meet the holistic needs of the healthcare professional. With flexible technology, now everyone from the institution to the individual can have access to education in a single space, including product focused, clinical, and beyond. The first subscription offering MRI PRO, with a library of 300 PIRADS scored multi parametric prostate MRI cases, is now available on PEPconnect.   MRI PRO Co-Founder & Chairman, Assoc Prof Jeremy Grummet MBBS, MS, FRACS, said: “As an organisation, we are committed to improve the safety, precision, and efficiency of prostate cancer biopsy, and recognise the hugely important role MRI diagnostics can play. However, ensuring all healthcare professionals can gain the necessary experience to maximise the value of this methodology within the prostate cancer pathway, is key. We are pleased to partner with Siemens Healthineers with the aim of improving the overall patient experience and delivering the best possible health outcomes.”   MRI PRO is an e-learning platform that trains radiologists, urologists and trainee specialists through online case-based learning-by-doing, complete with full histological verification for instant feedback. The program offers quality images validated against the standard of tissue histopathology, and provides the opportunity to earn CME and CPD points. All cases on MRI PRO are acquired and reported to PIRADS v.2 specifications.  Users submit their answers on PIRADS score, location of index lesions and staging information for each case, and get instant feedback, including access to the actual histo pathology report. MRI PRO is uniquely positioned to have a significant impact on the way that doctors diagnose the disease and manage the treatment of men. MRI PRO is also accredited by the European Accreditation Council for Continuing Medical Education (EACCME), the American Medical Association (AMA), the Royal Australasian College of Surgeons, and the Royal Australian and New Zealand College of Radiologists to earn CME points. Developed in Australia for radiologists and urologists around the world, MRI PRO is the world's largest online trainer in prostate MRI. Team of the world's top experts from universities including Cambridge, Stanford, University of California San Francisco and New York University have advised on the program.  For more information, or to see the tool in action, head to How To Find the best App Development Company in Melbourne 2020-02-18T12:26:06Z how-to-find-the-best-app-development-company-in-melbourne There are several options that you can choose from when it comes to app development in Melbourne. It is now possible for people from different parts of the world to share and use applications using the mobile Internet and electronic communication devices. These days, popular mobile phone makers are not making money in manufacturing cell phones; instead, they are developing apps for the new generation of users. Some companies are paying hundreds of dollars to developers to make software for their apps, in return, these companies will get exclusive rights to a mobile phone model. One of the best ways to develop an app in Melbourne is to work with a professional developer who can design the app and run it on a mobile device, including an Android or iOS device. There are plenty of companies that offer mobile app development services in Melbourne. If you prefer an e-mailed version of the app, developers can also do that for you. One of the advantages of mobile app development in Melbourne is that you will have the option to use a mobile phone which is similar to a normal cellphone and run it on the Internet. All you need to have is the physical access to a PC and you can run the app on any platform that has a web browser. Finding a mobile application development company in Melbourne is simple. Just search the Internet and you will see several results that may be useful to you. You must spend some time evaluating each of them so that you can select the best one for your business. One of the things that you will need to consider when choosing a mobile app development company is the price. They may charge you according to the number of lines of code they need to develop your app, how much money they expect to spend on your design, and whether they are willing to give you access to their servers. All of these factors should be taken into consideration before selecting the best one. Another factor that you will need to consider when you are selecting a mobile app development service is the expertise of the developer. Do not get too emotional about the cost or the price and just do your due diligence to find out about their experience and training. If you are very experienced with mobile app development, then you can ask questions. Find out what the company's policy is with regards to rebates, refunds, and other terms and conditions. If you cannot find answers to your questions, then it is best to find another company. You can also ask the developer about how to pay for the work they have done. Usually, you have to pay monthly or quarterly for their services, so consider this when you are choosing a developer. If you have your budget set, and you know you are comfortable with the price, then choose a developer that has a lower price because he has more experience. Mobile app development in Melbourne offers a lot of opportunities to you. The app you develop will be used by hundreds of thousands of people all over the world and can earn you a lot of money in the process. Media Release: MDMA-assisted psychotherapy for bushfire victims - Fast-tracked access needed for breakthrough PTSD treatment 2020-02-13T11:30:31Z mdma-assisted-psychotherapy-for-bushfire-victims It is estimated that 800,000 Australians suffer from post-traumatic stress disorder (PTSD). Mental health experts predict this staggering figure will rise sharply as a result of the trauma experienced by families and first responders who have had their lives or safety threatened by the catastrophic bushfires this summer.In response to this mental health crisis, Mind Medicine Australia (MMA) has called for the fast-tracking of access to MDMA-assisted psychotherapy for the treatment of PTSD. MMA is a not-for-profit organisation established to promote the development of research-backed and regulatory-approved Medicine-Assisted Therapy in Australia.Doctors typically treat people who have PTSD with psychotherapy and pharmaceutical medicines. But the medications can often produce unpleasant side effects and show a mere 20%-30% success rate for patients. Exposure therapy is more successful, providing relief from PTSD in around half of cases. However, the treatment process can be long and extremely gruelling, causing many patients to drop out.In contrast, recent clinical trials of MDMA-assisted psychotherapy in the United States have shown to relieve PTSD immediately after just three active dose sessions for 54% of participants. A 2018 study specifically in first responders and veterans showed that patients improved further at a 12-month follow up with 67% of them in remission. The results of a separate study showed than an astounding 76% of participants did not meet the clinical diagnostic criteria for PTSD a year after the conclusion of treatment.The research has been so promising that the American Food and Drug Administration (FDA) granted MDMA-assisted psychotherapy Breakthrough Therapy status in 2017. The FDA is expected to give full regulatory approval for the treatment in the next few years after the current Phase 3 trials are completed. Earlier this month, however, an Expanded Access Program was authorised by the FDA that permits the use of MDMA-assisted psychotherapy in the United States this year, ahead of the conclusion of clinical trials. Similarly, Israel, Switzerland, and Canada have recently begun Compassionate Use Schemes that enable PTSD patients to access this therapy.Peter Hunt AM, Chair of MMA, says that Australia needs to follow the lead of these countries quickly. “These medicines have been proven to be very safe when used as part of psychotherapy in a clinically controlled environment. The Australian Therapeutic Goods Act allows the use of medicines which are not listed on the Therapeutic Goods Register under the Special Access Scheme. Australia needs to act now and expedite the availability of MDMA-assisted psychotherapy through this program to relieve the suffering of bushfire victims and others with PTSD.” Tania de Jong AM, Executive Director of MMA, agrees that an urgent shift in approach is needed. “The Australian government has allocated $76 million for distress counselling and mental health support for those affected by the bushfires. Despite the best of intentions, the current treatment methods don’t help all people who have developed PTSD. The evidence shows that MDMA-assisted psychotherapy not only works but, in the long term, will also be highly cost-effective for taxpayers.” Bushfire-affected people who have developed PTSD may experience ongoing feelings of panic or extreme fear. Without effective treatment, the debilitating symptoms can last for many years or even a lifetime. It is a condition that can act as a catalyst in a person for depression, substance abuse, and suicide, and is linked to unemployment, homelessness, and family violence.Statistics show that 10% of first responders have PTSD, and a third of them endure high psychological distress. They have suicidal thoughts at twice the rate of adults in the general population, and one first responder takes his or her own life every six weeks.According to the Productivity Commission’s 2019 Mental Health Report, the total cost of mental illness and suicide to the Australian economy is $180 billion per year.MDMA used in Medicine-Assisted Therapy and within a clinically controlled environment is not the street drug Ecstasy. Substances sold illegally often have adulterants and are usually taken in risky settings with high doses. The medicine is not a cure in itself but a facilitator for the therapeutic process. It decreases activity in the amygdala, part of the brain associated with traumatic memory, and reduces fear and defensiveness while increasing empathy, trust, and safety. Only two or three active dose sessions are needed in contrast to antidepressant treatments that usually require daily medications. Due to the ease of the treatment process, patient adherence rates are much higher with MDMA-assisted psychotherapy compared to other psychotherapies, like exposure therapy. Like MDMA, mounting clinical research indicates that psilocybin, a naturally occurring compound derived from what is colloquially known as magic mushrooms, can provide highly effective solutions for various mental illnesses when used in a clinically controlled environment in conjunction with psychotherapy. Studies show that both these medicines are physiologically safe and are not addictive. Universities that have researched these medicine-assisted psychotherapies include Harvard, Oxford, Cambridge, NYU, Imperial College, Yale, and Kings College, among many others.Mind Medicine Australia is co-funding Australia’s first clinical trial of Medicine-Assisted Therapy at St Vincent’s Hospital in Melbourne. Participating palliative care patients experiencing depression and anxiety are being treated with psilocybin. Mind Medicine Australia anticipates that more clinical trials will be announced at major research institutions in Australia soon.MMA was founded by social entrepreneurs Peter Hunt AM and Tania de Jong AM following their successful experience setting up other charities and working with people diagnosed with a mental illness. Visit for comprehensive information about the organisation. For all media enquiries, including interviews and images, please contact: Brad Grimshaw, Communications Consultant E:  M: 0476 230 970 Tania de Jong AM, Executive Director E:  M: 0411 459 999 MRI PRO & BXTACCELYON ON A MISSION TO COMBAT INACCURATE DIAGNOSIS OF PROSTATE CANCER 2020-02-11T01:56:43Z mri-pro-amp-bxtaccelyon-on-a-mission-to-combat-inaccurate-diagnosis-of-prostate-cancer With high-level evidence[1] now confirming prostate MRI’s place in the diagnostic process of prostate cancer detection, as well as adoption of the methodology in NICE[2], EAU[3], AUA[4] and national and international urology and radiology guidelines, demand for healthcare professionals experienced in interpreting and accurate reporting of MRI scans is skyrocketing. Gaining the experience that is required for accurate interpretation of prostate MRI is essential, l but is difficult to obtain without the availability of immediate histological feedback. MRI PRO addresses this global, unmet need.   MRI PRO is a subscription-based e-learning platform that allows healthcare professionals to test themselves on 300 of the highest quality histology-verified prostate MRI cases. All cases on MRI PRO are acquired and reported to PIRADS v.2 specifications, including access to histology reports.  Users submit their answers on PIRADS score, location of index lesions and staging information for each case, and get instant feedback on how they did, including access to the actual biopsy report. MRI PRO is uniquely positioned to have a significant impact on the way that doctors diagnose the disease and manage the treatment of men.   MRI PRO is also accredited by the European Accreditation Council for Continuing Medical Education (EACCME), the American Medical Association (AMA), the Royal Australasian College of Surgeons, and the Royal Australian and New Zealand College of Radiologists to earn CME points.   MRI PRO Co-Founder & Chairman, Assoc Prof Jeremy Grummet MBBS, MS, FRACS, said: “As an organisation, we are committed to improve the safety, precision, and efficiency of prostate cancer biopsy, and recognise the hugely important role MRI diagnostics can play. However, ensuring all healthcare professionals can gain the necessary experience to maximise the value of this methodology within the prostate cancer pathway, is key. These are values which are also closely mirrored by the team at BXTAccelyon; their approach to training whole prostate cancer teams in the PrecisionPoint biopsy device is one we welcome, and are keen to mirror. We are pleased to partner with BXTAccelyon with the aim of improving the overall patient experience and delivering the best possible health outcomes.”   Saheed Rashid, Managing Director, BXTAccelyon, adds: “Earlier and better detection of prostate cancer is proven to widen the available treatment options to patients, which will improve outcomes whilst reducing potential adverse side-effects and / or relapse. In recent years, we have made great strides in transforming traditional biopsy techniques, however, it is still the case that we currently diagnose cancers that are harmless, leading to unnecessary investigations and operations, and we miss cancers that are harmful.    “Prostate MRI represents the next stage in prostate cancer diagnosis, but there is an unmet demand for education and training in MRI imaging and interpretation by urologist and radiologist. BXTAccelyon is therefore delighted to be the global distribution partner for this online learning platform that is paving the way for MRI education.” Made in Australia for radiologists and urologists around the world, MRI PRO is the world's largest online trainer in prostate MRI. A team of the world's top experts from universities including Cambridge, Stanford, University of California San Francisco and New York University have advised on the program.  For more information, or to see the tool in action, head to   About MRI PRO PTY LTD: MRI PRO is a world’s industry standard online prostate MRI training tool designed to help doctors and health care professionals required to accurately diagnose prostate cancer scans from MRI machines and to learn how best to interpret these images.  For media enquiries and/or high-resolution images please contact [1] [2] [3] [4]